IE59424B1 - Diazinylpiperidine derivatives - Google Patents
Diazinylpiperidine derivativesInfo
- Publication number
- IE59424B1 IE59424B1 IE182686A IE182686A IE59424B1 IE 59424 B1 IE59424 B1 IE 59424B1 IE 182686 A IE182686 A IE 182686A IE 182686 A IE182686 A IE 182686A IE 59424 B1 IE59424 B1 IE 59424B1
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- methyl
- pyrrolidinone
- piperidinyl
- pyrimidinyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
- 239000001257 hydrogen Substances 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 11
- 150000002367 halogens Chemical class 0.000 claims abstract description 11
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000005977 Ethylene Substances 0.000 claims abstract description 9
- 230000019771 cognition Effects 0.000 claims abstract description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 5
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 150000003950 cyclic amides Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 150000003949 imides Chemical class 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002524 organometallic group Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- LZAYRLDDBVAEHL-UHFFFAOYSA-N 1-[(1-pyrimidin-2-ylpiperidin-4-yl)methyl]pyrrolidin-2-one Chemical compound O=C1CCCN1CC1CCN(C=2N=CC=CN=2)CC1 LZAYRLDDBVAEHL-UHFFFAOYSA-N 0.000 claims description 2
- JVQLRYRCSOTTOU-UHFFFAOYSA-N 1-[[1-(6-chloropyrazin-2-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound ClC1=CN=CC(N2CCC(CN3C(CCC3)=O)CC2)=N1 JVQLRYRCSOTTOU-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 5
- KMAORAXOICONAN-UHFFFAOYSA-N 1-[(1-pyrimidin-2-ylpiperidin-2-yl)methyl]pyrrolidin-2-one Chemical compound O=C1CCCN1CC1N(C=2N=CC=CN=2)CCCC1 KMAORAXOICONAN-UHFFFAOYSA-N 0.000 claims 1
- RVWMZVAAMBTKHT-UHFFFAOYSA-N 1-[[1-(4,6-dichloropyrimidin-2-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound ClC1=CC(Cl)=NC(N2CCC(CN3C(CCC3)=O)CC2)=N1 RVWMZVAAMBTKHT-UHFFFAOYSA-N 0.000 claims 1
- JAGAFYRCPMXOJP-UHFFFAOYSA-N 1-[[1-(4-chloropyrimidin-2-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound ClC1=CC=NC(N2CCC(CN3C(CCC3)=O)CC2)=N1 JAGAFYRCPMXOJP-UHFFFAOYSA-N 0.000 claims 1
- ZQDRMIQUVAOMCS-UHFFFAOYSA-N 1-[[1-(5-bromo-2-chloropyrimidin-4-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound ClC1=NC=C(Br)C(N2CCC(CN3C(CCC3)=O)CC2)=N1 ZQDRMIQUVAOMCS-UHFFFAOYSA-N 0.000 claims 1
- FLTWFRMUCHUGDA-UHFFFAOYSA-N 1-[[1-(5-bromopyrimidin-2-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound N1=CC(Br)=CN=C1N1CCC(CN2C(CCC2)=O)CC1 FLTWFRMUCHUGDA-UHFFFAOYSA-N 0.000 claims 1
- MKNKZTFXTWZZLU-UHFFFAOYSA-N 1-[[1-(5-fluoropyrimidin-2-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound N1=CC(F)=CN=C1N1CCC(CN2C(CCC2)=O)CC1 MKNKZTFXTWZZLU-UHFFFAOYSA-N 0.000 claims 1
- FXWJYWSKTOGXJN-UHFFFAOYSA-N 1-[[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound N1=CC(I)=CN=C1N1CCC(CN2C(CCC2)=O)CC1 FXWJYWSKTOGXJN-UHFFFAOYSA-N 0.000 claims 1
- SGBGKRCKWFSTHS-UHFFFAOYSA-N 1-[[1-(6-chloropyridazin-3-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound N1=NC(Cl)=CC=C1N1CCC(CN2C(CCC2)=O)CC1 SGBGKRCKWFSTHS-UHFFFAOYSA-N 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000001777 nootropic effect Effects 0.000 abstract description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 2
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 abstract description 2
- 230000006883 memory enhancing effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 26
- 239000000543 intermediate Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 230000035939 shock Effects 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 208000000044 Amnesia Diseases 0.000 description 15
- 208000031091 Amnestic disease Diseases 0.000 description 15
- 230000006986 amnesia Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000007920 subcutaneous administration Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Chemical group 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- ZUNGTEUNVMHDIX-UHFFFAOYSA-N (1-pyrimidin-2-ylpiperidin-4-yl)methanol Chemical compound C1CC(CO)CCN1C1=NC=CC=N1 ZUNGTEUNVMHDIX-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010039966 Senile dementia Diseases 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- QMAXUUVHHTYNHC-UHFFFAOYSA-N ethyl 1-pyrimidin-2-ylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=CC=N1 QMAXUUVHHTYNHC-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960003389 pramiracetam Drugs 0.000 description 4
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000005543 phthalimide group Chemical class 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 229960004526 piracetam Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RSBPZNJHHVMXKF-UHFFFAOYSA-N 1-(piperidin-4-ylmethyl)pyrrolidin-2-one;hydrate;hydrochloride Chemical compound O.Cl.O=C1CCCN1CC1CCNCC1 RSBPZNJHHVMXKF-UHFFFAOYSA-N 0.000 description 2
- NMKHSQHHAFEVRR-UHFFFAOYSA-N 1-(piperidin-4-ylmethyl)pyrrolidin-2-one;hydrochloride Chemical compound Cl.O=C1CCCN1CC1CCNCC1 NMKHSQHHAFEVRR-UHFFFAOYSA-N 0.000 description 2
- NDNXTOYJPCXQBT-UHFFFAOYSA-N 1-[[1-(2-chloropyrimidin-4-yl)piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound ClC1=NC=CC(N2CCC(CN3C(CCC3)=O)CC2)=N1 NDNXTOYJPCXQBT-UHFFFAOYSA-N 0.000 description 2
- XEOONRMTEFSPSW-UHFFFAOYSA-N 2-[4-(chloromethyl)piperidin-1-yl]pyrimidine Chemical compound C1CC(CCl)CCN1C1=NC=CC=N1 XEOONRMTEFSPSW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960000793 aniracetam Drugs 0.000 description 2
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 239000007806 chemical reaction intermediate Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 229910052801 chlorine Chemical group 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- XVFVMXHZBURBPL-UHFFFAOYSA-N 1-(piperidin-1-ylmethyl)pyrrolidin-2-one Chemical compound O=C1CCCN1CN1CCCCC1 XVFVMXHZBURBPL-UHFFFAOYSA-N 0.000 description 1
- KEWFMWJJMGQBAN-UHFFFAOYSA-N 1-[[1-[2-(trifluoromethyl)pyrimidin-4-yl]piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C1=NC=CC(N2CCC(CN3C(CCC3)=O)CC2)=N1 KEWFMWJJMGQBAN-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- WLDMPODMCFGWAA-UHFFFAOYSA-N 3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione Chemical group C1CCCC2C(=O)NC(=O)C21 WLDMPODMCFGWAA-UHFFFAOYSA-N 0.000 description 1
- OVEGSCLVOXWLIV-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC=CC(Cl)=N1 OVEGSCLVOXWLIV-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Nootropic compounds of Formula I wherein X is an ethylene chain or a 1,2-benzo ring; Y is carbonyl or methylene; R<1> is hydrogen or lower alkyl; and Z is an R<2>, R<3>-disubstituted diazinyl ring selected from pyridazine, pyrimidine, and pyrazine ring systems, where R<2> and R<3> are selected from H, C1-4 alkyl, alkoxy or alkylthio, CN, CF3, C2F5 or halogen, possess cognition and memory enhancing activity.
Description
This invention generally pertains to heterocyclic . carbon compounds having drug and bio-affecting properties and to their preparation and use. In particular, the invention is concerned with disubstituted piperidine derivatives wherein one substituent is a cyclic amide or imide ring linked by a bridging methylene moiety to one of the carbon ring positions of the piperidine ring and the other substituent is a diazinyl ring system, attached to the piperidine nitrogen atom. The compounds of this invention are applicable in treatment of various senile dementias affecting the elderly.
The clinical aspects of various senile dementias as well as the problems they cause in the affected geriatric subject are well known to those skilled in the art. One will also appreciate that various drug treatments of this disorder of the elderly are currently under study. Among such drugs are a class of drugs known as nootropic agents or, more commonly, cognition enhancers; some of which are currently undergoing clinical evaluation in patients diagnosed as having Alzheimer’s disease, a serious and fairly common CNS disorder of the elderly. Chemically, these drugs under clinical study are members of a class of N-substituted 2-pyrrolidinone derivatives of structure 1. b: d: ,ο n-r X = H; R = -CHjCONHj (piracetam) X = OH; R = -CH2CONH2 (oxiracetam) X = H; R = -CH2CONH[CH2J2NtCH(CH3)2J2 (pramiracetam) X = H; R = -CO (^y-OCH^ (aniracetam) For a representative reference describing the testing and properties of a member of this series 1., see Butler, et al., J. Med. Chem., 27, pp. 684-691 (1984). Preliminary clinical results with this class of agents, exemplified by structures la-d, indicates that these drugs may have some beneficial effects in treating senile dementias in the elderly.
Related art may be viewed in light of the following general structural formula 2 in which X is c2-4 alkylene or a 1,2-benzo ring; Y is carbonyl or methylene; A is a bridging moiety such as alkylene, alkanoyl, alkyleneamidoalkylene, and the like; W is nitrogen or CH; and B is an aryl or pyrimidinyl ring system. The most closely related art is that disclosed and claimed in our own pending continuation-in-part application U.S.S.N. 799,670, filed November 11, 1985. The subject matter relates to a series of formula 2 compounds wherein W is nitrogen. The closest related compounds disclosed in that application may be characterized by structural formula 3. 2 wherein R is hydrogen or lower alkyl; and R can also be hydrogen or lower alkyl. As can be seen, these earlier j compounds are structurally distinguishable from the present series of compounds on the basis of chemical structure as these earlier compounds are piperazine ring derivatives (W = N in Formula 2) whereas the present- compounds are piperidine ring derivatives (W = CH in Formula 2).
Other subject matter related to formula 3 compounds has been disclosed by Malawska, et al., in Synthesis and Pharmacological Properties of Some 2-Pyrrolidinone Mannich Bases in the Polish Journal of Pharmacology, 1982, 34, 373-382. They describe a series of compounds, of which one subclass is represented by structural formula 4, which reportedly display analgesic properties as well as weak anti-inflammatory action, wherein X is hydrogen or chlorine.
A large number of psychotropic compounds with structures corresponding to formula 2 wherein Y is carbonyl, W is nitrogen, and A is C2_^ alkylene have been disclosed by Wu, Temple, New, and their co-workers and others. These compounds are comprised of cyclic imide rings, e.g. succinimides, glutarimides, phthalimides, etc. The shortest linkage defined by A in these compounds is ethylene as compounds wherein A is methylene are too unstable, particularly in acidic media, for practical usage. For more detailed disclosure of these compounds, see: Wu, et al., U.S. Patent 3,717,634 patented February 20, 1973; Temple, U.S. Patent 4,423,049 patented December 27, 1983; and New and Yevich, U.S. patent 4,524,206 patented June 18, 1985.
Increasing structural departure from compounds of the present invention is found in other art cited in our above-referenced application. In summary, the present diazinylpiperidine compounds described herein are structurally novel cognition·enhancing agents and there are no teachings in the art which would make the specific compounds comprising this invention anticipated or obvious.
The invention provides compounds of the following Formula I, and pharmaceutically acceptable acid addition salts thereof: wherein X is an ethylene chain or a 1,2-benzo ring; Y is carbonyl or methylene, with the proviso that Y is carbonyl only when X is a 1,2-benzo ring; R^ is hydrogen 2 3 or C 4 alkyl; and Z is an R ,R -disubstituted diazinyl ring selected from pyridazine, pyrimidine, and pyrazine 2 3 ring systems. R and R are independently chosen from hydrogen, lower (C1-4) alkyl, lower alkoxy, lower alkylthio, cyano, lower perfluoroalkyl, and halogen. Compounds of this series can be incorporated into pharmaceutical compositions for intended use in geriatric subjects afflicted with senile dementias. A representative number of these compounds have been tested and demonstrate prevention of ECS-induced amnesia in rats.
The present invention provides in fact certain 1_(4-diaziny1)piperidiny1 derivatives of N-methylene cyclic amides and imides having psychogeriatric properties and being characterized by the above Formula I.
In Formula I, X is a C2 (ethylene) alkylene chain or a 1,2-benzo ring connecting Y and the carbonyl group to give, e.g. when Y is also carbonyl, a phthalimide moiety. Y is a carbonyl group (but only when X is a 1,2-benzo ring) or C^. In Formula I, r\ can be either hydrogen or lower 2 3 alkyl; and Z is an R ,R -disubstituted diazmyl ring selected from pyridazine, pyrimidine, and pyrazine ring 2 3 systems, with R and F being independently chosen from hydrogen, lower alkyl, lower perfluoroalkyl (such as trifluoromethyl or pentafluoroethyl), lower alkoxy, lower alkylthio, cyano, and halogen. By lower alkyl is meant that these groupings contain from 1 to 4 carbon atoms. Halogen means F, Cl, Br, or I. For preferred compounds, X is 2 3 ethylene, Y is methylene, R is hydrogen, and R and R are selected from hydrogen, trifluoromethyl, and halogen, with the most preferred halogen being chloride.
It is to be understood that the present invention is considered to include the various stereoisomers, e.g. optical isomers including individual enantiomers, mixtures of enantiomers, diastereomers, and mixture of diastereomers, which can arise as a consequence of structural asymetry due to the presence of one or two asymetric carbon atoms which may be incorporated in some compounds of the present series. Separation of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. For medicinal use, the pharmaceutically acceptable acid addition salts, those salts in which the anion does not contribute significantly to toxicity or pharmacological activity of the organic cation may be preferred in some cases. The acid addition salts are obtained either by reaction of an organic'base of structure I with an organic or inorganic acid, preferably by contact in solution, or by any of the standard methods detailed in the literature available to any practitioner skilled in the art. Examples of useful organic acids are carboxylic acids such as maleic acid, acetic acid, tartaric acid, propionic acid, fumaric acid, isethionic acid, succinic acid, pamoic acid, cyclamic acid, pivalic acid, and the like; useful inorganic acids are hydrohalide acids such as HCl, HBr, HI? sulfuric acids; phosphoric acids; and the like. Additionally, the present invention also encompasses any of the Formula I compounds existing in solvate form such as a hydrate.
The compounds of the present invention can be conviently prepared by means of a general process which is shown in Scheme 1.
Scheme 1 General Synthetic Process IX co2C2H5 + z-Cl CO2C2H5 —I— CHO VIII VII LAH In Scheme 1, the symbols X, Y, and Z are as previously defined. Basically» a piperidine earboxylate ester (IX) is coupled with an appropriate diazine halide (VIII). While an ethyl ester and a chloride group are shown in compounds IX and VIII, respectively, in Scheme 1, other equivalent groups, e.g. another alkyl earboxylate ester and/or a different halogen may be used. These alterations would be familiar to an organic chemist skilled in synthesis of compounds. Typically, the reaction of IX and VIII will take place in a reaction solvent such as acetonitrile in the presence of a base such as potassium carbonate, thereby giving the product (VII). The VII product may· either be reduced with lithium aluminum hydride in an appropriate solvent such as tetrahydrofuran to give reaction intermediate VI (R^=H) or, alternatively, VII may be converted to the aldehyde X using standard methods for ester transformation into an aldehyde moiety, and this followed by treatment with an organo metallic reagent, R^M (wherein M represents the appropriate metal cation or Grignard complex) to give the intermediate product VI'. The primary alcohol intermediate (VI) or secondary alcohol (VI*) is treated with thionyl chloride to give the corresponding chloro compound (V) which is then coupled with a selected cyclic amide or imide (IV) to give the desired product of Formula I. This coupling reaction proceeds similarly to that of IX and VIII with a preferred reaction solvent in this case being dimethylformamide and incorporating a base such as potassium carbonate. It will be understood by those skilled in the art that other conversions of VI intermediates may be made which would effectively convert the hydroxy group into a different leaving group (e.g. a tosylate or mesylate moiety) in order to facilitate alkylation of the nitrogen atom in the cyclic amide/imide compound.
Another process may be utilized to produce products of Formula I and this process is set forth as Scheme 2.
Scheme 2 Synthetic Process When X is an Ethylene Chain In Scheme 2, R^, X, Y, and Z are as previously defined. While the process outlined in Scheme 2 generally produces products of Formula I in higher yields than the general process of Scheme 1, it does not have the general - applicability of Scheme 1. Because of the catalytic reduction (conversion of III to II) only cyclic amides/imides impervious to catalytic reduction may be used. For example, when X is a 1,2-benzo ring, e.g. IV is phthalimide, the benzo ring moiety is subsequently reduced ’·· to a 1,2-cyclohexyl derivative, thereby giving a hexahydrophthalimide ring system.
To summarize the foregoing, there is-described a process for the preparation of a compound of Formula I I wherein R1, X, Y, and Z are as previously defined. This process comprises selection of a process from the group of processes consisting of (a) (1) coupling compounds IX and VIII H Z-q VIII IX wherein R is a ci_g alkyl group and 0 is a suitable displacement group such as chloride, bromide, iodide, sulfate, phosphate, tosylate, mesylate, or the like to give an intermediate product of Formula VII; Z Vll (2) submitting the intermediate product, VII, to (i) treatment with lithium aluminum hydride, where R1 is to be hydrogen, or (ii) conversion into the aldehyde wherein -CHO replaces the -CO R followed by treatment with an organometallic ά i reagent R M, wherein M is a metal ion or complex, e.g. a Grignard reagent complex, where R1 is to be either hydrogen or lower alkyl, to give the reaction intermediate of Formula VI; Z VI (3) treating intermediate VI with an appropriate reagent to convert the OH group of VI to a leaving group Q in the compound of Formula V; Z V and 4) reacting intermediate V with a cyclic amide/imide compound of Formula IV IV (b) ( to give a product of Formula I; ) reacting a cyclic amide/imide compound of Formula IV, r\.
IV wherein X is not a 1,2-benzo ring, with a pyridine intermediate of Formula X X to give the intermediate compound of (2) catalytically reducing the compound of Formula III to give the piperidine intermediate compound of Formula II II and (3) coupling the compound of Formula II with compound Z-Q to give a product of Formula I.
Compounds of the present invention have been evaluated for nootropic activity using as a primary screen the reversal of electroconvulsive shock-induced amnesia for a step-down passive avoidance response (cf: Banfis, et al., J. Pharmacol. Meth., 8, 255 (1982); Janvik, Ann. Rev. Psychol., 22, 457 (1972); and, McGaugh and Petrinovich, Int. Rev. Neurobiology, 8, 139 (1965)). Reference compounds such as pramiracetam, piracetam, aniracetam, etc., having activity in this paradigm have been purported to affect memory processes and may be useful in treating senile dementia and Alzheimer's disease. In this test, 12 animals are administered drugs and 30 minutes later are trained to remain immobile to avoid foot shock. Immediately following -- the training, the animals are given electroconvulsive shock.
Twenty-four hours later the animals are tested for retention of the learned behavior; and any animal which remains on the. platform for 300 seconds without stepping down is considered to have retained the passive avoidance response. Two groups of control animals are used for comparison; one group receives vehicle with electroconvulsive shock and the other receives vehicle with sham-electroconvulsive shock. A test compound is considered active at a given dosage level if the mean latency to step-down is both statistically greater than the value for the electroconvulsive shock control group Λ (placebo control group) and not statistically different from the value for the sham-electroconvulsive shock·control group.
A test compound is considered to have intermediate activity at a given dosage level if results for the drug group are statistically different from both control groups. For the sake of comparison, all drugs were tested after subcutaneous administration; however, preferred compounds of the instant series exhibit activity following ofal administration that is little changed from the results following subcutaneous administration of drug. In this regard the following compounds are particularly preferred: 1-[[1-(2-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone, 1-[[1-(2-chloro-4-pyrimidinyl)-4-piperidinyl]methyl]-2pyrrolidinone, 1-[[1-(6-chloro-2-pyrazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone and, especially, 1-[[1-(2-trifluoromethy1-4-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone. Maintenance of comparable levels of potency in going from subcutaneous to oral administration is a considerable dosing advantage and distinguishes the instant compounds from agents described in prior art references. Additionally, the present compounds are not labile in acidic media which is another advantage in their manufacture, formulating, shipping and storage, as well as for dosing.
In summary of the foregoing discussion, the present compounds have nootropic properties particularly suited to their, use in cognition and memory enhancement.
Thus, the present invention makes possible a process for enhancing cognition and memory in a mammal in need of such treatment which comprises systemic administration to such mammal of an effective dose of a Formula I compound or a pharmaceutically acceptable acid addition salt thereof. The administration and dosage regimen of compounds of Formula I is considered to be done in the same manner as for the reference compound piracetam, cf: Reisberg, et al., in Drug Development Research, 2:475-480 (1982); Weng, et al., in Rational Drug Therapy, 17(5), 1-4 (1983); Reisberg, et al., in Psychopathology in the Aged, Editors, Cole and Barrett, Raven Press, New York, pages 243-245 (1980) and pramiracetam, cf: Butler, et al, J. Med. Chem., 27, pp 684-691 (1984).
✓ In addition to the usefulness of the compounds of Formula I as cognition enhancing agents or mild stimulants of the central nervous system, the compounds have been found to be useful in preventing amnesia which tesults from electroconvulsive shock. Such activity not only relates to memory retention in normal aging and senility processes but would be useful in protecting against the amnesia-producing effects of electroconvulsant shock as it is used clinically Electroconvulsant shock is employed to treat some classes o psychiatric patients, particularly depressed patients who are refractory to traditional pharmacologic therapy. It is well documented that these electroconvulsant shock . treatments induce the undesirable side-effect of amnesia in those patients to whom it is administered. The present compounds which exhibit activity in protecting against the amnesia-producing effects of electroconvulsant·shock in pharmacologic testing would be useful adjuncts to the clinical use of electroconvulsant shock in psychiatric treatment.
Although the dosage and dosage regimen must in each case be carefully adjusted, utilizing sound professional judgment and considering the age, weight and condition of the recipient, the route of administration and the nature and extent of mental deterioration, generally, the daily dose will be from about 0.1 g to about 10 g, preferably 0.5 g to 5 g, when given orally. In some instances, a sufficient therapeutic effect can be obtained at lower doses while in others, larger doses will be required. As is apparent to one skilled in clinical pharma cology, the amount of Formula I compound comprising the daily dose may be given in a single or divided dose, taking into account those principles understood by the skilled practitioner and necessary for his practice of the art.
The term systemic administration as used herein refers to oral, sublingual, buccal, nasal, dermal, rectal, intramuscular, intravenous, and subcutaneous routes. Generally, it will be found that when a compound of the present invention is administered orally which is the preferred route, a slightly larger quantity of the active drug is required to produce the same effect as a somewhat smaller quantity when given parenterally. In accordance with good clinical practice, it is preferred to administer the present compounds at a concentration level which will produce effective nootropic effects without causing any harmful or untoward side effects.
Therapeutically, the present compounds are generally given as pharmaceutical compositions comprised of an effective nootropic amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier. Pharmaceutical compositions for effecting such treatment will contain a major or minor amount (e.g. from 95% to 0.5%) of at least one compound of the present invention in combination with a pharmaceutical carrier, the carrier comprising one or more solid, semi-solid, or liquid diluent, filler and formulation adjuvant which is non-toxic, inert and pharmaceutically acceptable. Such pharmaceutical compositions are preferably in dosage unit forms; i.e., physically discrete units having a pre-determined amount of the drug corresponding to a fraction or multiple of the dose which is calculated to produce the desired therapeutic response. In usual practice, the dosage units contain 1, 1/2, 1/3, or less of a single dose. A single dose preferably contains an amount sufficient to produce the desired therapeutic effect upon administration at one application of one or more dosage units according to the pre-determined dosage regimen, usually a whole, half, third, or less of the daily dosage administered once, twice, three, or more times a day. It is envisioned that other therapeutic agents can also be present in such a composition. Pharmaceutical compositions which provide from 0.1 to 1 g of the active ingredient per unit dose are preferred and are conventionally prepared as tablets, losenges, capsules, powders, aqueous or oily suspensions, syrups, elixirs, and aqueous solutions. Preferred oral compositions are in the form of tablets, capsules, and may contain conventional excipients such as binding agents (e.g., syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone), fillers (e.g. lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine), lubricants (e.g. magnesium stearate, talc, polyethylene glycol or silica), disintegrants (e.g. starch) and wetting agents (e.g. sodium lauryl sulfate). Solutions or suspensions of a Formula I compound with conventional pharmaceutical vehicles are employed for parenteral compositions such as an aqueous solution for intravenous injection or an oily suspension for intramuscular injection.
Such compositions having the desired clarity, stability and adaptability for parenteral use are obtained by dissolving from about 0.1% to 10% by weight of the active compound in water or a vehicle consisting of a polyhydric aliphatic alcohol such as glycerine, propylene glycol, and the polyethylene glycols or mixtures thereof. The polyethylene glycols consist of a mixture of non-volatile, usually liquid, polyethylene glycols which are soluble in both water and organic liquids and which have molecular weights from about 200 to 1500.
The compounds which constitute this invention and their methods of preparation as well as their biological activity will appear more fully from a consideration of the following examples which are given for the purpose of illustration only and are not to be construed as limiting the invention in sphere or scope. All temperatures are understood to be in degrees C when not specified. The nuclear magnetic resonance (NMR) spectral characteristics refer to chemical shifts (δ ) expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the proton (PMR) spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shift as to multiplicity is reported as broad singlet (bs), singlet (s), multiplet (m), doublet (d), doublet of doublets (dd), triplet (t), or quartet (q). Abbreviations employed are DMSO-dg (perdeuterodimethylsulfoxide), CDCl^ (deuterochloroform) and are otherwise conventional. The infrared (IR) spectral descriptions include only absorption wave numbers (cm-1) having functional group identification value. The IR determinations were employed using potassium bromide (KBr) as diluent. All compounds gave satisfactory elemental analysis.
EXAMPLE 1 2-[[1-(2-Pyrimidinyl)-4-piperidinyl]' methyl]-lH-isoindole-1,3-(2H)-dione This synthetic sequence exemplifies the more general synthesis outlined in Scheme 1, supra.
A. Ethyl 1-(2-Pyrimidinvl)piperidine-4carboxylate (VII).- A mixture of ethyl isonipecotate (IX; 31.44 g, 0.2 mole), 2-chloropyrimidine (VIII; 22.91 g, 0.2 mole), and potassium carbonate (27.69 g, 0.2 mole) in acetonitrile (250 mL) was refluxed for 24 hour. The mixture was filtered and the filtrate concentrated in vacuo. The residue was distilled (130-170° at 0.32 Torr.) to give 44.1 g (94%) of product in the form of a clear oil.
B. 4-Hydroxymethyl-l-(2-pyrimidinyl)piperidine (VI).- A solution of the ester (VII; 20 g, 0.085 mole) in tetrahydrofuran (200 mL) was cooled to 0-5° and lithium aluminum hydride (3.23 g, 0.085 mole) was slowly added over a 10 minute period. The mixture was stirred at room temperature for 30 minutes. The excess LAH was quenched with acetone and the mixture diluted by adding 3.2 mL of water followed by 3.2 mL of 15% sodium hydroxide solution and then 9.7 mL of water. The resulting mixture was filtered and the filtrate concentrated in vacuo to given an oil which was distilled to give 15 g (91%) of a clear oil product, b.p. 140-190° at 0.3 torr.
C. 4-Chloromethyl-l-(2-pyrimidinyl)piperidine (V).- A solution of the hydroxymethyl compound (VI; 7.73 g, 0.04 mole) in methylene chloride (40 mL) was cooled to 0-5° and thionyl chloride (25 mL) was added slowly. The solution was stirred for 12 hours at ambient temperature and then concentrated in vacuo. The residue was dissolved in methylene chloride, extracted with aqueous sodium bicarbonate, and the methylene chloride layer concentrated in vacuo. The residue was chromatographed on silica gel using ethyl acetate as the eluent to give 7.7 g (91%) of product as an oil.
D. Reaction of Intermediate V and Phthalimide.A mixture of potassium carbonate (2.76 g, 0.02 mole), phthalimide (1.47 g, 0.01 mole), and 4-chloromethyl-l-(2pyrimidinyl)piperidine (V; 2.12 g, 0.01 mole) in dimethylformamide (50 mL) was heated to about 50° for 24 hours. the dimethylformamide solvent was removed in vacuo and the residue was dissolved in acetone and filtered. The filtrate was concentrated in vacuo to give the crude product which was chromatographed on silica gel using 30% ethyl acetate-hexane as the eluent. The product was then recrystallized from ethyl acetate to yield 0.95 g (20.5%) of product in the form of white crystals, m.p. 109-111°.
Anal. Calcd. for ^gH^N^O?: C, 67.06; H, 5.64; N, 17.38. Found: C, 66.95; H, 5.68; N, 17.17.
NMR (CDC13): 1.35 (2fm); 1.74 (2,m); 2.10 (l,m); 2,85 (2,m); 3.61 (2,d, 7.0 Hz); 4.76 (2,m); 6.40 (l,t, 4.8 Hz); 7.79 (4,m); 8.27 (2,d, 4.8 Hz).
IR (KBr): 730, 800, 1360, 1400, 1515, 1540, 1590, 1710, 1750, and 2930 cm1.
EXAMPLE 2 1-((1-(2-Pyrimidinyl)-4piperidinylImethyl]-2-pyrrolidinone This experimental sequence exemplifies the synthetic process that can be used when X of the Formula I compound is an alkylene chain (see Scheme 2, supra.) A. 1-((4-Piperidinyl)methyl]-2-pyrrolidinone Hydrochloride Hydrate (II).- A solution of 1- (4-pvridinylmethyl)-2-pyrrolidinone hydrochloride (III; 15.05 g, 0.0707 mole; prepared from 2-pyrrolidinone and 4-pyridinvImethyl chloride), HCl (10 mL of an 8N solution in absolute ethanol) and absolute ethanol (100 mL) was hydrogenated at 60 psi with PtO2 (1.0 g) for 72 hour. The mixture was filtered and the filtrate reduced in vacuo to give a white solid. The crude product was recrystallized from isopropanol to give 13.03 g (83%) of product as a white powder, m.p. 212-214°.
B. Reaction of Intermediate Compound II With 2- Chloropyrimidine.- A mixture of the piperidinylmethylpyrrolidinone (II; 5.08 g, 0.0232 mole), 2-chloropyrimidine (2.67 g, 0.0233 mole) and potassium carbonate (7.09 g, 0.0513 mole) in dimethylformamide (60 mL) was heated in a 50-100° oil bath for 14 hour. The mixture was cooled and filtered. The solvent was then removed in vacuo and the residue chromatographed on silica gel using an ethyl acetate-acetone mixture as the eluent to give 4.7 g (78%) of product as white crystals, m.p. 144-147°.
Anal. Calcd. for c14H20N4O: C, 64.59; H, 7.74; N, 21.52. Found: C, 64,26; H, 7.78; N, 21.20.
NMR (CDC13): 1.29 (2,m); 1.71 (2,m); 2.01 (3,m); 2.34 (2,t, 7.4 Hz); 2,84 (2,m); 3.16 (2,d, 7.0 Hz); 3.39 (2,t, 6.8 Hz); 4.73 (2,m); 6.40 (l,t, 4.7 Hz); 8.26 (2,d, 4.7 Hz).
IR (KBr): 800, 1360, 1440, 1515, 1540, 1585, 1675, and 2930 cm"^).
EXAMPLE 3 1-[[1-(2-Chloro-4-pyrimidinyl)-4piperidinyl]methyl]-2-pyrrolidinone A mixture of 1-[(4-piperidinyl)methyl]-2pyrrolidinone hydrochloride (II, prepared above in Example 2A; 20.1 g, 0.0922 mole), 2,4-dichloropyrimidine (14.90 g, 0.1 mole), sodium carbonate (26.5 g, 0.25 mole), and 200 mL dimethylformamide was stirred for 14 hour at room temperature and then heated to 70° for one hour. The mixture was filtered and concentrated in vacuo. The crude residue was chromatographed on silica using ethyl acetate/methanol (95:5) as the eluent thereby separating the product residue into two components. The major component / was obtained as 16 g (59%) of off-white powder, m.p. 110-114, and represented the desired 2-chloro-4-pyrimidinyl isomer.
Anal. Calcd. for c14Hi9clN4°·· C, 57.04; H, 6.50; N, 19.01. Found: C, 56.73; H, 6.44; N, 18.97.
NMR (CDC13): 1.30 (2,m); 1.78 (2,m); 2.03 (3,m); 2.39 (2,t, 7.4 Hz); 2.92 (2,m); 3.17 (2,d, 7.0 Hz); 3.40 (2,t, 6.8 Hz); 4.35 (2,m) ; 6.39 d,a, 6.0 Hz); 7.98 l,d, 6.0 Hz) . IR (KBr): 965, 1150, 1350, 1360, 1490 , 1590, 1685, 2860, and 2950 cm-1 • EXAMPLE 4 1- ((1- (4-Chloro-2-pyrimidinyl) ] -4«piperidinyl]methyl]-2-pyrrolidinone The other isomer, the 4-chloro-2-pyrimidinyl compound, was obtained from the smaller component obtained by chromatography and recrystallization from ethyl acetate of the reaction product of Example 3 (above) to give 1.1 g (4%) of white crystals, m.p. 143.5-145.5°.
Anal. Calcd. for C14H39ClN4O: C, 56.04; H, 6.50; N, 19.01. Found: C, 56.66; H, 6.49; N, 19.81.
NMR (CDC13): 0.9-2.1 (5,m); 2.25 (2,t, 5 Hz); 2.75 (2,t, 8Hz); 3.10 (2,d, 5Hz); 3.30 (2,t, 5 Hz); 4.5-4.8 (2,d; 6.45 (l,d, 4 Hz); 8.13 (l,d, 4 Hz).
IR (KBr): 1275, 1350, 1419, 1512, 1525, 1588, and 1688 cm"1.
EXAMPLE 5 1-((1-(6-Chloro-2-pyrazinyl)-4piperidinylImethyl]-2-pyrrolidinone Using the procedure described above in Examples 2 and 3, a mixture of 1-[(4-piperidinyl)methyl]-2-pvrrolidinone hydrochloride (II, 12.5 g, 0.0556 mole); 2,6-dichloropyrazine (8.37 g, 0.0556 mole); potassium carbonate (19.2 g, 0.139 mole); and DMF (150 mL) was stirred at room temperature for 14 hour and then heated to 70° for one hour. The mixture was filtered and the filtrate concentrated in vacuo. The crude product was recrystallized twice from ethyl acetate to provide 11.16 g (68%) of tan crystals, m.p. 139-142°.
Anal. Calcd. for C^H^CIN^: C, 57.04; H, 6.50; N, 19.01. Found: C, 57.02; H, 6.40; N, 19.03.
NMR (CDC13): 1.34 (2,m); 1.77 (2,m); 2.05 (3,m); 2.40 (2,t, 7.2 Hz); 2.91 (2,m); 3.18 (2,d, 7.0 Hz); 3.40 (2,t, 6.8 Hz); 4.30 (2,m); 7.74 (l,s); 7.96 (l,s).
IR (KBr): 835, 1140, 1275, 1415, 1460, 1490, 1500, 1565, 1685, 2840, and 2945 cm-1.
EXAMPLE 6 1-((1-(2-(Trifluoromethyl)-4-pyrimidinyl]4-piperidinyl]methyl]-2-pyrrolidinone Using the procedure described above in Examples 2 and 3, a mixture of 1-[(4-piperidinyl)methyl]-2-pyrrolidinone hydrochloride (II, 21.85 g, 0.1 mole) and sodium carbonate (26.5 g, 0.25 mole) in methanol (150 mL) was refluxed for one hour. The methanol was then removed in vacuo, and acetonitrile (150 mL) was added to the residue.
The mixture was cooled and stirred as 4-chloro-2-(trifluoromethyl) -pyrimidine (18.28 g, 0.1 mole) was added. The mixture was stirred at room temperature for 18 hours and then filtered and the filtrate concentrated in vacuo to give a thick residue which solidified upon being washed with hexane (100 mL). The light tan powder (23.8 g, 73%) which resulted was chromatographed (5% methanol/ethyl acetate on silica) to give 19.8 g as white crystals, m.p. 118.5-120.5°.
Anal . Calcd. for C^^H^gF^N^O: C, 54.87; H, 5.83; 10 N, 17.07. Found: C, 54.50; H, 5.86; N, 16.80. Λ In similar manner a number of additional compounds of Formula I were prepared and are tabulated in Table 1.
Table 1 Compounds of Formula I - Ex. Rx X Piperidine Y Ring-link Z_ Formula’ H -C-H.- CH- 32 4 2 C14H20N4° H -C-H.- CH- 22 4 2 C14H20N4° -C2h4- CH2 4(H-Cl C14H19C1N4° H -C-H.- CH2 4 2 F c15h21fn4os 11 H "C2H4 CH2 4" τ Ci4h19fn4o Cl H C2H4 CH2 C14H18C12N4° H "C2H4- CH2 C14H18C12N4° H -C-H.- CH- 42 4 2 -Q Cl c14h19cin4o m.p.(°) 105.5107.5 110- 113 138139.5 96-100 134-136 140- 144 111114.5 141142.5 Table 1 - Continued Ex. R X H -C2h4Piperidine CH.
Formula c15H2iclN4° H C2H4_ CH_ 4- C15H21C1N4° CH, H _C2H4 CH2 4_ — Br C^H^gBr^O H -C2H4- CH2 4N-\ 43C1 C14H19C1N4° H -C2H4- CH2 4- "^Z1 C14H19IN4° H -C2H4- CH2 4- Me C15H21C1N4OS Cl 21 H -C-H.- CH- 42 4 2 Cl Cl -o· C14H18CW H CH, 4· 4 2 Br C14H18BrC1N4C OMe H -C-H.- CH- 4· 2 4 2 c15H22N4°2 H -C2H4- CH2 4« CN ' Ci§HPh3§ m.p. f°) 133- 135 104-107 143-146 130-133 129.5131.5 134- 137 135- 138 105-115 116-121 139.5- ‘ 142 Table 1 - Continued Ex. R X Piperidine Y Ring Link Z Formula' m.p.(°) H l,2-CgH4 CH2 4C18H20N4° 176178 H —C_H.- CH- 4· 4 2 -d c16H19F5N4° 105-107.5 CF, H -C-H.- CH- 4· 4 2 Cl C.-H1BC1F-N.O 10213 10 ύ 4 104.5 H -C-H.- CH- 4· 4 2 CiCH,OFCN.0 132.5620 134 C, H, and N analyses were value. all within + 0.4% of the calculated EXAMPLE 29 Reversal of ECS-induced Amnesia for Step-Down Passive Avoidance Response In the step-down passive avoidance procedure, rats are trained to remain immobile to avoid foot shock. Two control groups (n=36/group) were required; and ECS control and a sham-ECS control. ECS control animals were placed individually on a platform over an activated shock grid (0.8 mA) 30 min. after vehicle administration. The animals readily stepped down from the platform, immediately experienced the foot shock, and quickly learned to escape to the platform. An animal was considered to have acquired the passive avoidance response if it remained on the platform for 2 minutes without stepping down following foot shock delivery. Immediately after acquisition, the ECS control animals were delivered ECS via transcorneal electrodes at an intensity of 50 nA for 400 msec. The sham-ECS control animals were treated in a manner identical to that described for the ECS controls, with the exception that current was not passed through the transcorneal electrodes. Both groups were administered a retention test 24 hours later. Animals were placed individually on the platform, and the latency to step down from the platform onto the unactivated shock grid was recorded; a given subject animal considered to have retained the passive avoidance response if it remained on the platform for 300 seconds without stepping down.
Sham-ECS controls remain on the platform during this test, showing normal retention; ECS controls readily stepped down within 300 seconds, exhibiting a deficit in retention (i.e., amnesia).
Step-down latency scores were transformed into percent retention scores with 300 seconds equal 100% retention. The percent retention scores for all drugs groups were evaluated against both the ECS and sham-ECS control groups using Dunnett's test. A compound was considered to be active in this test if the mean retention score obtained from at least one dose group is both significantly greater than the ECS control group retention and not significantly different from the sham-ECS control group retention. This indicates that the test compound reversed the amnesia for the passive avoidance task induced by the ECS. The compounds which statistically raised the animal's performance above that of the ECS control group, but did not raise the performance sufficiently to be not statistically different from the sham-ECS control group were scored as possessing intermediate activity. These compounds, then, do statistically raise the animals' performance, but not sufficiently to give total protection against the amnesia.
The biological activities of selected Formula I compounds in the test outlined in Example 29 are given in Table 2.
Table 2 Biological Activities of Selected Formula I Compounds in Reversal of ECS-induced Amnesia for a Step-Down Passive Avoidance Response Name ECS-induced Amnesia Reversal pramiracetam (reference compound) 2-((1-(2-Pyrimidinyl)-4piperidinyl]methyl]-1Hisoindole-1,3-(2H)-dione active3 at 10 mg/kg s.c active at 10 mg/kg s.c. 3 9 1-((1-(2-Pyrimidinyl)-4piperidinyl]methyl]-2pyrrolidinone Λ 1-( [1-(2-Chloro-4pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 1-( (l-(6-Chloro-2pyrazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 1-((1-(2- (Trif luoro methyl) t4pyrimidinYi ] -4-piperidinyl ] methyl ] -Z-pycrolidinone 1-((1-(2-Pyrimidinyl)-3piperidinvl]methyl]-2pyrrolidinone 1-( [1-(2-Pyrimidinyl)-2piperidinvl]methyl]-2pyrrolidinone 1-( [1-(6-Chloro-3pyridazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 1-((1-(5-Fluoro-4-(methylthio) -2-pyrimidinyl]-4piperidinyl]methyl]-2pyrrolidinone active at 10 mg/kg s.c. and p.o. active at 0.5 mg/kg s.c and p.o. active at 0.5 mg/kg s.c active at 0.25 to 10 mg/kg p.o., active at 0.5 to 10 mg/kg s.c. active at 25 mg/kg s.c. active at 25 mg/kg s.c. active at 25 mg/kg s.c. intermediate activity at 10 and 25 mg/kg s.c. 1-((1-(5-Fluoro-2- active at 10 mg/kg s.c. pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone Table 2 - Continued Ex.
Name l-[[1-(2,6-Dichloro-4pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone l-[ [1-(4,6-Dichloro-2pyrimidinyl)-4piperidinyl]methyl]-2pyrrolidinone 1-[[1-(6-Chloro-4pyrimidinyl)-4piperidinyl]methyl]-2pyrrolidinone 1- [ [1-(2-Chloro-6-methyl4-pyrimidinyl)-4piperidinyl]methyl]-2pyrrolidinone 1-[[1-(5-Bromo-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone l-[ [1-(5-Chloro-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 1-F[l-(5-Iodo-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 1-[[1-(5-Bromo-2-chloro-4pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 1-[[1-(2-Methoxy-4pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone 4- [4-[(2-0xopyrrolidin1- yl)methyl]-1-piperidinyl]2- pyrimidinecarbonitrile 1-f[1-[2-(Pentafluoroethyl)4-pyrimidinyl]-4-piperidinyl ]methyl]-2pyrrolidinone ECS-induced Amnesia Reversal active at 1.0 mg/kg s.c Intermediate activity at 10 mg/kg s.c. intermediate activity at 10 mg/kg s.c. intermediate activity at 10 mg/kg s.c. active at 10 & 25 mg/kg p.o. active at 10 mg/kg p.o. active at 25 mg/kg p.o. active at 0.5-1.0 mg/kg p.o. intermediate activity at 10 mg/kg p.o. active at 25 mg/kg p.o. intermediate activity at 10 mg/kg Table 2 - Continued ECS-induced Ex. Name Amnesia Reversal 1-[[1-(5-Chloro-2- intermediate activity (trifluoromethyl)-4- at 10 mg/kg p.o. pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone 1-[[1-[2,6-bis(trifluoro- active at 10 mg/kg p.o. methyl)-4-pyrimidinyl]-4piperidinyl]methyl]-2pyrrolidinone a. Active denotes compounds which completely reversed the ECS-induced amnesia while intermediate activity denotes less than complete protection.
Claims (39)
1. A compound of Formula I wherein X is an ethylene chain or a 1,2-benzo ring; Y is a carbonyl group or -CH 2 -, with the proviso that Y is carbonyl only when X is a 1,2-benzo ring; is selected from hydrogen or C^_ 4 alkyl; and 2 3 Z is an R -, R - disubstituted diazinyl ring selected from pyridazine, pyrimidine, and 2 3 pyrazine ring systems, with R and R being independently chosen from hydrogen, lower (C^_ 4 ) alkyl, lower alkoxy, lower alkylthio, cyano, lower .perfluoroalkyl, and halogen; or a pharmaceutically acceptable acid addition salt thereof.
2. A compound of claim 1 wherein X is ethylene' and R 1 is hydrogen. 2 3
3. A compound of claim 1 wherein R and R are independently selected from hydrogen, halogen, and 5 trifluoromethyl. 2 3
4. A compound of claim 2 wherein R‘ and R are independently selected from hydrogen, halogen, and trifluoromethyl.
5. The compound of claim 1, 2-[[1-(2-pyrimi10 dinyl)-4-piperidinyl]methyl]-ΙΗ-isoindole-l,3-(2H)-dione.
6. The compound of claim 1, 1-[[1-(2-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
7. The compound of claim 1, 1-[ fl-(2-chloro-4pyrimidinyl) -4-piperidinylImethyl ] -2-pyrrolidinone. 15
8. The compound of claim 1, 1-[ [1-(4-chloro-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
9. The compound of claim 1, 1-[[1-(6-chloro-2pyrazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
10. The compound of claim 1, 1-[[1-[2-(trifluoromethyl) -4-pyrimidinyl]-4-pip.eridinyl Jmethyl J-2-pyrrolidinone .
11. The compound of claim 1, 1-[Γ1-(2-pyrimidinyl) -3-piperidinvl]methyl]-2-pyrrolidinone. 5
12. The compound of claim 1, 1-[[1-(2-pyrimidinyl) -2-piperidinyl]methyl]-2-pyrrolidinone.
13. The compound of claim 1, 1-[ [1-(6-chloro-3pyridazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
14. The compound of claim 1, 1-([1-(5-fluoro-4-|q (methylthio) -2-pyrimidinyl] -4-piperidinyl]methyl] -2pyrrolidinone.
15. The compound of claim 1, 1-[[1-(5-fluoro-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
16. The compound of claim 1, 1-[[1-(2,6-dichloro15 4-pyrimidinyl)-4-piperidinylJmethyl]-2-pyrrolidinone.
17. The compound of claim 1, 1-[[1-(4,6-dichloro2-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
18. The compound of claim 1, 1-[[1-(6-chloro-4pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrblidinone.
19. The compound of claim 1, l-([l-(2-chloro-6methy1-4-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone
20. The compound of claim 1, 1-[[1-(4-chloro-6methyl-2-pyrimidinyl)-4-piperidinylImethyl]-2-pyrrolidinone
21. The compound of claim 1, 1-[ [1-(5-bromo-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
22. The compound of claim 1, 1-[[1-(5-chloro-2i pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
23. The compound of claim 1, 1-[[1-(5-iodo-2pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
24. The compound of claim 1, 1-[(1-(6-chloro2-(methylthio)-4-pyrimidinyl]-4-piperidinyl]methyl]-2pyrrolidinone.
25. The compound of claim 1, 1-((1-(5,6dichloro-4-pyridazinyl)-4-piperidinyl]methyl]-2-pyrrolidinone.
26. The compound of claim 1, 1-[[1-(5-bromo2-chloro-4-pyrimidinyl)-4-piperidinyl]methyl]-2-pyrrolidinone .
27. The compound of claim 1, 1-((1-(2-methoxy 4-pyrimidinyl)-4-piperidinyllmethyl]-2-pyrrolidinone.
28. The compound of claim 1, 4-(4-(2-oxopyrrolidin-l-yl)methyl]-1-piperidinyl]-2-pyrimidine5 carbonitrile.
29. The compound of claim 1, 1-[ (1-ί2-(pentafluoroethyl) -4-pyrimidinyl]-4-piperidinyl]methyl]-2pyrrolidinone.
30. The compound of claim 1, 1-[ [ 1-(5-chloro10 trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl] 2-pyrrolidinone.
31. The compound of claim 1, 1-[ [ 1-[2,6-bis(trifluoromethyl)-4-pyrimidinyl]-4-piperidinylJmethyl]2-pyrrolidinone. 15
32. Medication comprising an effective dose of a compound claimed in claim 1, for use in a method for enhancing cognition and memory in a mammal in need of such treatment which comprises systemic administration of medication to the mammal.
33. A process to produce a compound of the formula wherein X is an ethylene chain or a 1, 2 - benzo ring; Y is carbonyl or methylene, with the proviso that Y is carbonyl only when X is a 1,2-benzo ring; R 1 is hydrogen 2 3 or lower alkyl; Z is a R , R - disubstituted diazinyl ring selected from pyridazine, 2 3 pyrimidine, and pyrazine; and R and R are independently selected from hydrogen, lower alkyl, lower alkoxy, lower alkylthio, cyano, lower perfluoroalkyl and halogen which comprises alternatively (A) reacting a compound of the formula H IX wherein R is a Cj to C 6 alkyl group with a compound of the formula Z - Q wherein Z is as above and Q is a suitable displacement group (B) submitting the product of (A) to (i) treatment with lithium aluminum hydride, where R 1 is to be hydrogen, or (ii) conversion into the aldehyde wherein -CHO replaces the -CO ? R followed by treatment with an organometallic reagent R M, wherein M is a metal ion or complex, where R 1 is to be either hydrogen or lower alkyl (C) reacting the product of (B) with a reagent capable of converting the hydroxy group of the product of (B) to the substituent Q and (D) reacting the product of (C) with a cyclic amide/imide 5 of the formula IV wherein X and Y are as above to provide the product of Formula I or alternatively to produce a Formula I compound wherein X is an ethylene chain and Y, R 1 , R 2 , R 3 and Z are as above (A ) reacting a cyclic amide/imide of the formula IV with a compound of the formula wherein R 1 and Q are as above (B*) catalytically reducing the product of (A*) and (C*) coupling the product of (B*) with a compound of the formula wherein Z and G are as above to produce a compound of Formula I .
34. The process of claim 33 wherein Q is a displacement group selected from . a chloride, bromide, iodide, sulfate, phosphate, tosylate or mesylate group.
35. a process for producing a compound or salt as claimed in claim 1, substantially as described in respect of any of the foregoing Examples.
36. A compound or salt as claimed in claim 1, produced by a process as claimed in claim 33, 34 or 35.
37. a pharmaceutical composition comprising a compound or salt as claimed in any of claims 1 to 31, or claim 36, and a pharmaceutically acceptable carrier.
38. A pharmaceutical composition according to claim 37, substantially as hereinbefore described.
39. Use of a compound or salt as claimed in any one of claims 1-31 or 36, a medication according to claim 32 or a pharmaceutical composition according to claim 37 or 38 for enhancing cognition and memory in a mammal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75300685A | 1985-07-08 | 1985-07-08 | |
US86846886A | 1986-05-30 | 1986-05-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE861826L IE861826L (en) | 1987-01-08 |
IE59424B1 true IE59424B1 (en) | 1994-02-23 |
Family
ID=27115677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE182686A IE59424B1 (en) | 1985-07-08 | 1986-07-07 | Diazinylpiperidine derivatives |
Country Status (28)
Country | Link |
---|---|
KR (1) | KR940003756B1 (en) |
CN (1) | CN1012364B (en) |
AT (1) | AT395850B (en) |
AU (1) | AU595215B2 (en) |
BE (1) | BE905061A (en) |
CA (1) | CA1272725A (en) |
CH (1) | CH671579A5 (en) |
CY (1) | CY1630A (en) |
DE (1) | DE3622842C2 (en) |
DK (1) | DK170441B1 (en) |
EG (1) | EG18310A (en) |
ES (1) | ES2000476A6 (en) |
FI (1) | FI88300C (en) |
FR (1) | FR2584408B1 (en) |
GB (1) | GB2177692B (en) |
GR (1) | GR861765B (en) |
HK (1) | HK11292A (en) |
HU (1) | HU199455B (en) |
IE (1) | IE59424B1 (en) |
IL (1) | IL79351A (en) |
IT (1) | IT1196467B (en) |
NL (1) | NL8601763A (en) |
NO (1) | NO167389C (en) |
NZ (1) | NZ216720A (en) |
PT (1) | PT82942B (en) |
SE (1) | SE462491B (en) |
SG (1) | SG111091G (en) |
YU (2) | YU45017B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0351283A1 (en) * | 1988-07-12 | 1990-01-17 | Synthelabo | 2-[(4-Piperidinyl)methyl]-2,3-dihydro-1H-isoindole and 2,3,4,5-tetrahydro-1H-benzazepine derivatives, their preparation and therapeutical use |
FR2634208B1 (en) * | 1988-07-12 | 1990-11-23 | Synthelabo | ((PIPERIDINYL-4) METHYL) -2 DIHYDRO-2,3 1H-ISOINDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
EP0497843A4 (en) * | 1989-10-27 | 1992-09-23 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
US4963678A (en) * | 1989-10-27 | 1990-10-16 | Bristol-Myers Squibb Co. | Process for large-scale production of BMY 21502 |
US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
US5098904A (en) * | 1990-06-27 | 1992-03-24 | Bristol-Myers Squibb Company | Cerebral function enhancing pyrimidinyl derivatives |
US5240934A (en) * | 1990-10-19 | 1993-08-31 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US5190951A (en) * | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US5401744A (en) * | 1993-10-04 | 1995-03-28 | Bristol-Myers Squibb Company | Useful hemi-hydrate form of a cerebral function enhancing agent |
CN106188039B (en) * | 2016-06-30 | 2019-01-01 | 广东工业大学 | A kind of derovatives and the preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759371A (en) * | 1969-11-24 | 1971-05-24 | Bristol Myers Co | HETEROCYCLICAL AZASPIRODECANEDIONES AND METHODS FOR THEIR PREPARATION |
ZA76475B (en) * | 1975-03-10 | 1977-08-31 | Ciba Geigy Ag | Indolyalkylpiperidines |
EP0009465A1 (en) * | 1978-09-20 | 1980-04-02 | Ciba-Geigy Ag | N-(1-(4-amino-2-quinazolinyl)-3 or 4-piperidyl lactames, process for their preparation and pharmaceutical compositions containing them |
US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
US4524206A (en) * | 1983-09-12 | 1985-06-18 | Mead Johnson & Company | 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives |
-
1986
- 1986-07-01 NZ NZ216720A patent/NZ216720A/en unknown
- 1986-07-03 YU YU1186/86A patent/YU45017B/en unknown
- 1986-07-03 FI FI862830A patent/FI88300C/en not_active IP Right Cessation
- 1986-07-03 FR FR8609666A patent/FR2584408B1/en not_active Expired
- 1986-07-07 CH CH2740/86A patent/CH671579A5/de not_active IP Right Cessation
- 1986-07-07 IL IL79351A patent/IL79351A/en not_active IP Right Cessation
- 1986-07-07 GB GB8616504A patent/GB2177692B/en not_active Expired
- 1986-07-07 HU HU862835A patent/HU199455B/en unknown
- 1986-07-07 GR GR861765A patent/GR861765B/en unknown
- 1986-07-07 DK DK323986A patent/DK170441B1/en not_active IP Right Cessation
- 1986-07-07 NL NL8601763A patent/NL8601763A/en active Search and Examination
- 1986-07-07 AU AU59787/86A patent/AU595215B2/en not_active Expired
- 1986-07-07 IT IT21049/86A patent/IT1196467B/en active
- 1986-07-07 SE SE8603026A patent/SE462491B/en not_active IP Right Cessation
- 1986-07-07 CA CA000513196A patent/CA1272725A/en not_active Expired - Lifetime
- 1986-07-07 NO NO862729A patent/NO167389C/en not_active IP Right Cessation
- 1986-07-07 IE IE182686A patent/IE59424B1/en not_active IP Right Cessation
- 1986-07-07 BE BE0/216887A patent/BE905061A/en not_active IP Right Cessation
- 1986-07-08 AT AT0185286A patent/AT395850B/en not_active IP Right Cessation
- 1986-07-08 CN CN86104681A patent/CN1012364B/en not_active Expired
- 1986-07-08 EG EG416/86A patent/EG18310A/en active
- 1986-07-08 KR KR1019860005480A patent/KR940003756B1/en not_active IP Right Cessation
- 1986-07-08 DE DE3622842A patent/DE3622842C2/en not_active Expired - Lifetime
- 1986-07-08 ES ES8600190A patent/ES2000476A6/en not_active Expired
- 1986-07-08 PT PT82942A patent/PT82942B/en unknown
-
1987
- 1987-06-10 YU YU1073/87A patent/YU44947B/en unknown
-
1991
- 1991-12-31 SG SG1110/91A patent/SG111091G/en unknown
-
1992
- 1992-02-13 HK HK112/92A patent/HK11292A/en not_active IP Right Cessation
- 1992-07-10 CY CY1630A patent/CY1630A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4668687A (en) | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones | |
EP0563345B1 (en) | Novel 4-arylpiperazines and 4-arylpiperidines | |
KR101432112B1 (en) | New Carbonylated (aza)cyclohexanes as dopamine D3 receptor ligands | |
EP0463810B1 (en) | Heterocyclic compound and psychopharmaceutical composition containing same | |
US5338738A (en) | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines | |
IE59424B1 (en) | Diazinylpiperidine derivatives | |
EP0784055A1 (en) | Pyrimidinylpyrazole derivative | |
US4826843A (en) | Cerebral function enhancing diazinylpiperidine derivatives | |
EP0660822B1 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents | |
US5098904A (en) | Cerebral function enhancing pyrimidinyl derivatives | |
CA1250291A (en) | Psychogeriatric 1-(2-pyrimidinyl)-piperazinyl derivatives of 1-pyrrolidin-2-ones | |
EP0913393B1 (en) | Arylacetic amide derivative or salt thereof, and pharmaceutical comprising it | |
US5057524A (en) | 4-[diaryl)hydroxymethyl]-1-piperidinealkylcarboxylic acids, salts and esters useful in the treatment of allergic disorders | |
US5077295A (en) | Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides | |
EP1120410B1 (en) | Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors | |
KR100226328B1 (en) | 4-(4- or 6-(trifluoromethyl-2-pyridinyl))-1-piperazinylalkyl substituted lactams | |
JPH045675B2 (en) | ||
JPH0558633B2 (en) | ||
JPH09291090A (en) | Piperidinone and homopiperidinone derivative | |
JPH0242078A (en) | Condensed heterocyclic compound | |
HU210073A9 (en) | Novel n-hydroxyalkyl-substituted 1,2,3,6-tetrahydropyridine and piperidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |